RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06986785, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with advanced HCC confirmed by histology or cytology;

    Inclusion criterion 5

    If hepatitis B virus infection is negative or positive, the status of HBV surface antigen (HBsAg) should be confirmed by HBV serological test;

    Inclusion criterion 15

  3. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

    Inclusion criterion 9

    Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug;

    Exclusion criterion 3

    The cumulative dose of anthracyclines > 360 mg/m2 in previous (new) adjuvant therapy;

    Exclusion criterion 21

  4. ECOG score was 0-1;

    Inclusion criterion 8

  5. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;

    Inclusion criterion 12

  6. At least one measurable lesion meeting the RECIST v1.1 definition was required;

    Inclusion criterion 7

  7. Other malignant tumors within 5 years before the first treatment;

    Exclusion criterion 9

  8. Pregnant or lactating women;

    Exclusion criterion 22

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06986785, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Sign the informed consent form voluntarily and follow the protocol requirements;
  • Gender is not limited;
  • Age ≥18 years old and ≤75 years old;
  • Expected survival time ≥3 months;
  • Patients with advanced HCC confirmed by histology or cytology;
  • Consent to provide archived tumor tissue samples or fresh tissue samples from the primary or metastatic lesions;
  • At least one measurable lesion meeting the RECIST v1.1 definition was required;
  • ECOG score was 0-1;
  • The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  • No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  • Organ function level must meet the requirements;
  • Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;
  • Urinary protein ≤2+ or ≤1000mg/24h;
  • No cirrhosis or only Child-Pugh A cirrhosis;
  • If hepatitis B virus infection is negative or positive, the status of HBV surface antigen (HBsAg) should be confirmed by HBV serological test;
  • For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria:

  • Patients with active central nervous system metastases;
  • Who had participated in any other clinical trial within 4 weeks before the trial dose;
  • Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug;
  • Had undergone major surgery (investigator-defined) within 4 weeks before the first dose;
  • Systemic corticosteroids or immunosuppressive therapy is required within 2 weeks before study dosing;
  • Pulmonary disease defined as ≥ grade 3 according to NCI-CTCAE v5.0; A history of ILD/pulmonary inflammation requiring steroid treatment;
  • Serious systemic infection within 4 weeks before screening;
  • Patients at risk for active autoimmune disease or with a history of autoimmune disease;
  • Other malignant tumors within 5 years before the first treatment;
  • Human immunodeficiency virus antibody positive, active tuberculosis or hepatitis C virus infection;
  • Poorly controlled hypertension by two antihypertensive drugs with different mechanisms;
  • Diabetic patients with poor glycemic control;
  • Had a history of severe cardiovascular and cerebrovascular diseases;
  • Previous history of autologous or allogeneic stem cell, bone marrow or organ transplantation;
  • Subjects with clinically significant bleeding or significant bleeding tendency within the previous 4 weeks were screened;
  • Patients with massive or symptomatic effusions or poorly controlled effusions;
  • Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large arteries or invaded the pericardium and heart;
  • Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  • Prior treatment with an ADC drug with a topoisomerase I inhibitor as a toxin;
  • Patients with a history of allergy to recombinant humanized antibodies or to any excipients of the trial drug;
  • The cumulative dose of anthracyclines > 360 mg/m2 in previous (new) adjuvant therapy;
  • Pregnant or lactating women;
  • Who have a history of psychotropic drug abuse and cannot quit or have mental disorders;
  • Other conditions for trial participation were not considered appropriate by the investigator.

Quoted from ClinicalTrials.gov, NCT06986785, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06986785, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06986785